RxDoctor Payments DataLook up a doctor →

David Eichenbaum, MD

Ophthalmology · St Petersburg, FLNPI 1144251356

Payments from drug & device makers

$34,404,335in general payments, 2019–2025

Across 3,674 payments — averaging $9364.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$12.9M
  • Genentech, Inc.$9.4M
  • Ocular Therapeutix, Inc.$2.2M
  • Roche TCRC, Inc.$1.8M
  • Bayer$1.5M
  • Janssen Research & Development, LLC$1.3M
  • plus $5.3M from 54 others
$44,963in research payments, 2019–2025

Across 23 payments — averaging $1954.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$39K
  • Regeneron$6K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis137$12,925,375
Genentech, Inc.668$9,364,980
Ocular Therapeutix, Inc.204$2,198,928
Roche TCRC, Inc.115$1,788,882
Bayer238$1,485,608
Janssen Research & Development, LLC73$1,324,026
AstraZeneca8$1,312,440
Regeneron490$987,693
Kyowa Kirin, Inc.187$809,699
Eyepoint US, Inc.74$585,858
AbbVie(2 entities)271$337,890
Genentech USA, Inc.290$304,970
Regeneron Healthcare Solutions, Inc.252$215,278
Apellis Pharmaceuticals, Inc.179$198,823
Astellas Pharma US Inc59$81,222
Mylan Technologies Inc.84$68,467
Sanofi US Services Inc.6$61,004
Astellas Pharma Global Development8$47,828
Grifols, S.A.7$46,384
F. Hoffmann-la Roche AG19$45,799
Alimera Sciences, Inc.57$25,610
Bausch & Lomb, A Division Of Bausch Health US, LLC24$24,199
Dutch Ophthalmic, USA27$23,405
Bausch & Lomb Americas Inc.26$21,231
US Retina LLC15$21,162
Grifols Biologicals LLC1$16,521
Novartis Pharma AG3$15,631
Bristol Myers Squibb9$11,470
Roche Products Limited4$8,863
Mylan Inc.1$7,167
Boehringer Ingelheim International GmbH22$6,932
Thrombogenics, Inc.5$5,296
Pfizer1$3,710
Hoffmann-la Roche Limited3$3,273
Harrow Eye, LLC16$3,004
ANI Pharmaceuticals, Inc.13$2,494
Alcon Research LLC3$2,382
Beaver-visitec International, Inc.1$1,635
Coherus Oncology, Inc.4$1,525
Notal Vision, Inc.2$1,321
Oculus Surgical Inc.3$1,194
W. L. Gore & Associates, Inc.1$900
Alcon12$855
E.r. Squibb & Sons, L.L.C.1$788
Mallinckrodt Hospital Products Inc.21$666
Natus Medical Incorporated1$337
Sandoz9$278
Amgen(2 entities)3$257
Biogen4$149
Kala Pharmaceuticals, Inc.1$125
Dompe US, Inc.1$122
Ivantis, Inc1$117
Spark Therapeutics, Inc.1$103
Glaukos Corporation1$100
Sanofi-aventis U.S. LLC1$99
Neurotech Pharmaceuticals, Inc.2$75
Carl Zeiss Meditec, Inc.1$70
Celltrion USA Inc.1$41
Samsara Vision1$41
Carl Zeiss Meditec AG1$19

How this compares

$34,404,335 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida →

Medicare billing

Part B allowed, 2024
$4,432,051
Medicare patients
902
Services billed
94,790

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other ophthalmology in St Petersburg

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →